terican

Last verified · v1.0

Calculator · health

Kidney Failure Risk Calculator (Tangri 4 Variable Kfre)

Estimate 2 or 5-year kidney failure risk using the validated 4-variable Tangri KFRE. Requires age, sex, eGFR, and urine albumin-to-creatinine ratio.

FreeInstantNo signupOpen source

Inputs

Kidney Failure Risk

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Kidney Failure Risk—

The formula

How the
result is
computed.

What Is the Kidney Failure Risk Calculator (KFRE)?

The Kidney Failure Risk Equation (KFRE) is a validated clinical prediction tool developed by Navdeep Tangri and colleagues, first published in JAMA in 2011. It estimates the probability that a patient with chronic kidney disease (CKD) will progress to kidney failure — defined as the need for dialysis or kidney transplantation — within a specified time horizon, most commonly 2 or 5 years. The 4-variable version uses age, sex, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (ACR) to generate a personalized risk estimate, making it one of the most widely adopted nephrology risk tools in clinical practice worldwide.

The KFRE Formula Explained

The calculator applies a proportional hazards survival model of the form: Risk = 1 − S0exp(βZ), where S0 is the baseline survival probability at the selected time horizon (0.9832 for 2 years; 0.9365 for 5 years in the original derivation cohort), and βZ is the linear predictor defined as:

βZ = −0.2201 × (age/10 − 7.036) + 0.2467 × (male − 0.5642) − 0.5567 × (eGFR/5 − 7.222) + 0.4510 × (ln(ACR) − 5.137)

Variable Breakdown

  • Age: Entered in years and divided by 10 in the formula. Validated in adults aged 18 and older with CKD stages 3–5.
  • Sex: Binary coefficient where male = 1 and female = 0. The centering value 0.5642 reflects the sex distribution of the derivation cohort.
  • eGFR: Estimated glomerular filtration rate in mL/min/1.73 m², preferably calculated with the CKD-EPI 2021 creatinine equation. Divided by 5 in the formula. Validated only for eGFR below 60 mL/min/1.73 m².
  • ACR: Urine albumin-to-creatinine ratio in mg/g. The natural logarithm of ACR enters the equation. To convert from mg/mmol to mg/g, multiply by 8.84.

Worked Example

Consider a 65-year-old male with an eGFR of 25 mL/min/1.73 m² and an ACR of 300 mg/g. Computing each term: age term = −0.2201 × (6.5 − 7.036) ≈ +0.118; sex term = +0.2467 × (1 − 0.5642) ≈ +0.107; eGFR term = −0.5567 × (5.0 − 7.222) ≈ +1.237; ACR term = +0.4510 × (ln(300) − 5.137) = +0.4510 × (5.704 − 5.137) ≈ +0.256. Summing these gives βZ ≈ 1.718, and the 5-year risk = 1 − 0.9365exp(1.718) = 1 − 0.93655.574 ≈ 30.5%. This patient has approximately a 30.5% probability of progressing to dialysis or kidney transplant within 5 years.

Clinical Validation and Evidence Base

The KFRE has been externally validated in over 700,000 patients across 31 countries, demonstrating excellent discrimination (C-statistic typically 0.83–0.90) and robust calibration across diverse populations. A multinational meta-analysis confirmed the accuracy of the 4-variable model across cohorts from North America, Europe, Asia, and Oceania, as detailed in Tangri et al. (PMC10103205). The equation is also embedded in the CDC Chronic Kidney Disease Risk Calculator platform, reflecting its broad acceptance in public health nephrology.

Clinical Applications

Clinicians use KFRE risk estimates to guide several high-stakes decisions in CKD management:

  • Nephrology referral timing — a 5-year risk above 10–20% commonly triggers earlier specialist involvement per KDIGO and NICE NG203 guidance
  • Shared decision-making about dialysis modality (hemodialysis vs. peritoneal dialysis) or pre-emptive transplant listing
  • Arteriovenous fistula creation planning, typically initiated when projected 1-year risk exceeds 15–25%
  • Identifying patients likely to benefit from renoprotective agents such as SGLT2 inhibitors or finerenone
  • Stratifying high-risk participants for clinical trials targeting CKD progression endpoints

Limitations and Appropriate Use

The KFRE applies exclusively to adults with eGFR below 60 mL/min/1.73 m² (CKD stages 3–5). It was not designed for pediatric populations, kidney transplant recipients, or patients with acute kidney injury. Those with polycystic kidney disease or a solitary kidney may show divergent risk profiles from the derivation cohort. Risk estimates should always be interpreted alongside the full clinical picture — CKD etiology, comorbidities, medication history, and patient preferences — rather than used in isolation to drive treatment decisions.

Reference

Frequently asked questions

What is the Kidney Failure Risk Equation (KFRE) and who developed it?
The KFRE is a validated clinical prediction model developed by Dr. Navdeep Tangri and colleagues, first published in JAMA in 2011. It uses four variables — age, sex, eGFR, and urine ACR — to estimate the probability of kidney failure requiring dialysis or transplantation within 2 or 5 years. Since its derivation, the model has been externally validated in over 700,000 patients across 31 countries, establishing it as the global standard for CKD progression risk stratification.
What eGFR range is the kidney failure risk calculator validated for?
The 4-variable KFRE is validated specifically for patients with an eGFR below 60 mL/min/1.73 m², corresponding to CKD stages 3a through 5. Applying the calculator to patients with an eGFR of 60 or above falls outside the validated range and may produce unreliable estimates. The CKD-EPI 2021 creatinine equation is the preferred method for estimating eGFR when using this tool in clinical practice.
How do I convert urine ACR from mg/mmol to mg/g for the KFRE?
To convert urine albumin-to-creatinine ratio from mg/mmol — the unit commonly reported in the United Kingdom, Canada, and Australia — to mg/g, the unit required by the KFRE formula, multiply the mg/mmol value by 8.84. For example, an ACR of 30 mg/mmol equals 30 × 8.84 = 265.2 mg/g. Always verify the units printed on the laboratory report before entering the ACR value into the calculator to avoid a significant input error.
What kidney failure risk percentage should prompt a nephrology referral?
Clinical guidelines vary, but many nephrologists use a 5-year KFRE risk exceeding 10–20% as a threshold for timely nephrology referral. Both KDIGO 2024 guidelines and NICE NG203 endorse risk-based stratification for CKD management decisions. Patients with a 5-year risk above 40% may also be appropriate candidates for pre-emptive kidney transplant evaluation or vascular access creation planning, since early preparation significantly improves patient outcomes on dialysis.
How accurate is the 4-variable KFRE compared to other CKD risk tools?
The 4-variable KFRE consistently achieves C-statistics between 0.83 and 0.90 across external validation cohorts, indicating excellent discriminative ability. A multinational meta-analysis published by Tangri et al. (available at PMC10103205) assessed accuracy across 31 international cohorts and confirmed robust performance. Importantly, the 4-variable model performs comparably to the more complex 8-variable version in most clinical settings, making it practical for routine use without requiring additional laboratory tests beyond eGFR and ACR.
Can the KFRE be used for kidney transplant recipients or pediatric patients?
No. The KFRE was derived and validated exclusively in non-transplant adult populations with CKD stages 3–5. Kidney transplant recipients experience fundamentally different trajectories of graft function decline and are not represented in the derivation cohort, making risk estimates unreliable in that group. Similarly, the equation has not been validated in children or adolescents. Clinicians assessing pediatric CKD progression risk should refer to separate validated models, such as those developed by the CKiD study consortium at Johns Hopkins.